IP Asthma - Evolution Biotechnologies - www.evolutionbiotech.com -
page-template-default,page,page-id-16269,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive


Intellectual property


The European Patent Office has now granted patent EP3331366, “Acaricides”, providing exclusivity for Evolution’s broad technological approach in Europe until 2036. The patent has also been granted in Hong Kong as patent HK1252537. A divisional application relating to composition of matter for formulated products has now been filed in Europe.


Corresponding applications are proceeding through examination in the USA, Australia, and Japan, leveraging our highly favourable PCT international examination report (IPRP).


The projected value of sales for biological control of the house dust mite into European markets is in excess of €500 million per annum.


The patent incorporates findings from Evolution’s successful feasibility study including the key identification of a novel biological control agent able to target multiple mite species. The granted claims provide broad protection to the whole area of biological control of house dust mites, with the first claim in the granted European patent reciting: “A method of treating or preventing a house dust mite infestation, said method comprising applying an acaricidal infectious agent at a site of a house dust mite infestation, or at a site proximal thereto, or at a site at risk of such infestation.”


Details of the European patent can be accessed on line at espacenet.com: